News | January 04, 2022
Domestic and emerging markets will drive pharma growth: ICRA
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Domestic business was up 41.9% YoY and 27.7% QoQ
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
As per National Health Accounts (NHA) estimates, government health expenditure rose steadily between 2013-14 and 2022-23, while out-of-pocket spending declined significantly
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
The company highlighted continued demand strength and pricing resilience despite global disruptions
Subscribe To Our Newsletter & Stay Updated
